Berotralstat reduces hereditary angioedema attacks requiring on-demand treatment in kids

Following receipt of once-daily berotralstat, pediatric patients with hereditary angioedema had a reduced rate of attacks requiring on-demand treatment early on in treatment, according to an updated interim analysis of the APeX-P study.These data on berotralstat (Orladeyo, BioCryst) were presented in a poster at the 2026 European Academy of Allergy and Clinical Immunology Annual Congress.